Fibrosis Models
Advanced fibrosis models that replicate key disease processes to accelerate antifibrotic drug development
At NEPHRIX Biosolutions, we have built a strong reputation in renal fibrosis research and expanded our expertise to other major fibrotic diseases. Using state-of-the-art preclinical models and advanced histological analyses, we accurately reproduce key mechanisms of fibrotic progression and assess therapeutic efficacy with strong translational relevance.
Building on this expertise, we offer a comprehensive range of in vivo fibrosis models across the Kidney, Heart, Lung, and Liver. Each model is designed to mirror organ-specific pathways of fibrotic development, enabling reliable evaluation of anti-fibrotic candidates.
We provide a comprehensive portfolio of models tailored to diverse research needs.
Our Kidney fibrosis models ensure high translational value for preclinical drug assessment:
Our Cardiac fibrosisis a hallmark of many cardiovascular diseases, leading to myocardial stiffening, impaired function and heart failure. We developped preclinical cardiac fibrosis models :
- DOcA-Salt + Ux rat model (Reactive fibrosis)
- Isoprenaline-induced MI (Reparative fibrosis)
Pulmonary fibrosis is a progressive scarring of lung tissue resulting from chronic injury or disease, which can ultimately lead to impaired respiratory function and respiratory failure. We offer preclinical pulmonary fibrosis models, including:s :
- Bleomycin (BLM)-induced pulmonary fibrosis
- Chronic pulmonary bacterial infection
Liver fibrosis is a progressive scarring of the liver tissue resulting from chronic injury or disease, which can ultimately lead to cirrhosis and organ failure. We offer rodent preclinical liver fibrosis models, including :
- Carbon tetrachloride (CCl4) induction
- High-fat & cholesterol diet (HFCD) induction, with hyperlipidemia